1. Capper, D, Sahm, F, Hartmann, C, Meyermann, R, von Deimling, A, Schittenhelm, J. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol. 2010;34:1199-1204.
Google Scholar | Crossref | Medline2. Kurtkaya-Yapicier, O, Scheithauer, BW, Hebrink, D, James, CD. P53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study. Neurosurgery. 2002;51:1246-54.
Google Scholar | Crossref | Medline3. Parsons, W, Jones, S, Zhang, Z, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-1821.
Google Scholar | Crossref | Medline4. Balss, J, Meyer, J, Mueller, W, Korshunov, A, Hatmann, C, von Deimling, A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597-602.
Google Scholar | Crossref | Medline5. Ali, A, Bell, S, Bilsland, A, et al. Investigating various thresholds as immunohistochemistry cutoffs for observer agreement. Appl Immunohistochem Mol Morphol. 2017;25:599-608.
Google Scholar | Crossref | Medline6. Horbinski, C, Kofler, J, Kelly, LM, Murdoch, GH, Marina, N, Nikiforova, MN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol. 2009;68:1319-1325.
Google Scholar | Crossref | Medline7. Lin, F, Chen, Z. Standardization of diagnostic immunohistochemistry literature review and geisinger experience. Arch Pathol Lab Med. 2014;138:1564-1577.
Google Scholar | Crossref | Medline8. Rivera-Zengotita, M, Tachnis, AT. Gliosis versus glioma? do not grade until you know. Adv Anat Pathol. 2012;19:239-249.
Google Scholar | Crossref | Medline9. Paulus, W. GFAP, Ki67 and IDH1: perhaps the golden triad of glioma immunohistochemistry. Acta Neuropathol. 2009;118:603-604.
Google Scholar | Crossref | Medline10. Villaamil, VM, Garcia, AA, Gallego, GA, et al. Tissue array analysis for the differentiation of gliosis from gliomas. Mol Med Rep. 2011;4:451-457.
Google Scholar | Medline11. Yaziji, H, Massarani-Wafai, R, Gujrati, M, Kuhns, J, Martin, A, Parker, JC. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Am J Surg Pathol. 1996;20:1086-1090.
Google Scholar | Crossref | Medline12. Camelo-Piragua, S, Jansen, M, Ganguly, A, et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol. 2011;70:110-115.
Google Scholar | Crossref | Medline13. Narasimhaiah, D, Miquel, C, Verhamme, E, Desclee, P, Cosnard, G, Godfraind, C. IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. Neuropathology. 2012;32:30-37.
Google Scholar | Crossref | Medline14. Anderson, MD, Abel, T, Moots, PL. Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry. Neuro Oncol. 2013;15:811-813.
Google Scholar | Crossref | Medline15. Choi, J, Lee, EY, Shin, KJ, Minn, YK, Kim, J, Kim, SH. IDH1 mutation analysis in low cellularity specimen: a limitation of diagnostic accuracy and a proposal for diagnostic procedure. Pathol Res Pract. 2013;209:284-290.
Google Scholar | Crossref | Medline16. Cahill, DP, Sloan, AE, Nahed, BV, et al. The role of neuropathology in the management of patients with diffuse low-grade glioma. A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015;125:531-549.
Google Scholar | Crossref | Medline17. Capper, D, Weibert, S, Balss, J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-254.
Google Scholar | Crossref | Medline